{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:19:58Z","timestamp":1783012798104,"version":"3.54.6"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012513","name":"Coins for Alzheimer's Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022504","name":"Dane G. Hansen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022504","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013356","name":"Cold Spring Harbor Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA53840"],"award-info":[{"award-number":["R01CA53840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA044508"],"award-info":[{"award-number":["CA044508"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH119819"],"award-info":[{"award-number":["R01MH119819"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.chembiol.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:03:13Z","timestamp":1781103793000},"page":"810-822.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-0102","authenticated-orcid":false,"given":"Prabhadevi","family":"Venkataramani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Fan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Altiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushabu","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokia","family":"Michalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Van Aelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Pappin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leemor","family":"Joshua-Tor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Al-Abed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K.","family":"Tonks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2026.05.005_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1742-4658.2010.07956.x","article-title":"Activation, regulation, and inhibition of DYRK1A","volume":"278","author":"Becker","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.chembiol.2026.05.005_bib2","doi-asserted-by":"crossref","first-page":"R488","DOI":"10.1016\/j.cub.2015.02.067","article-title":"DYRK protein kinases","volume":"25","author":"Soppa","year":"2015","journal-title":"Curr. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib3","first-page":"986","article-title":"Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition","volume":"21","author":"Soundararajan","year":"2013","journal-title":"Struct. Lond. Engl."},{"key":"10.1016\/j.chembiol.2026.05.005_bib4","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.chembiol.2026.05.005_bib5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1172\/JCI60455","article-title":"Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome","volume":"122","author":"Malinge","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.chembiol.2026.05.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134541","article-title":"microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing","volume":"714","author":"Chaves","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.chembiol.2026.05.005_bib7","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease","volume":"282","author":"Ryoo","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41598-017-00682-y","article-title":"Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice","volume":"7","author":"Yin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2026.05.005_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116233","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7","volume":"224","author":"Chu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2015.03.004","article-title":"DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications","volume":"151","author":"Abbassi","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.chembiol.2026.05.005_bib11","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1021\/acs.jmedchem.0c02050","article-title":"DYRK1A Inhibitors as Potential Therapeutics for \u03b2-Cell Regeneration for Diabetes","volume":"64","author":"Kumar","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib12","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1002\/cam4.4159","article-title":"DYRK1A activates NFATC1 to increase glioblastoma migration","volume":"10","author":"Liu","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.chembiol.2026.05.005_bib13","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1111\/jcmm.14609","article-title":"DYRK1A inhibition suppresses STAT3\/EGFR\/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291","volume":"23","author":"Li","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.chembiol.2026.05.005_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.20892\/j.issn.2095-3941.2019.0380","article-title":"DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors","volume":"17","author":"Li","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.chembiol.2026.05.005_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep36132","article-title":"A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma","volume":"6","author":"Radhakrishnan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2026.05.005_bib16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gutjnl-2018-316128","article-title":"DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth","volume":"68","author":"Luna","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.chembiol.2026.05.005_bib17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1172\/JCI63623","article-title":"Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth","volume":"123","author":"Pozo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.chembiol.2026.05.005_bib18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41419-021-03887-2","article-title":"K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.chembiol.2026.05.005_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.abb.2010.12.024","article-title":"Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)","volume":"507","author":"Adayev","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.chembiol.2026.05.005_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans","volume":"58","author":"De la Torre","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.chembiol.2026.05.005_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.05.005_bib22","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1021\/acs.jmedchem.6b01086","article-title":"Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules","volume":"59","author":"Rothweiler","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejmech.2015.02.035","article-title":"Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors","volume":"94","author":"Rothweiler","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib24","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/ph14111170","article-title":"Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome","volume":"14","author":"Stensen","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.chembiol.2026.05.005_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1039\/C8MD00142A","article-title":"Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core","volume":"9","author":"Salah","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.chembiol.2026.05.005_bib26","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1021\/acschemneuro.1c00475","article-title":"Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases","volume":"12","author":"Aboushady","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.chembiol.2026.05.005_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113911","article-title":"Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A\/\u03b1-synuclein aggregation inhibitors with neuroprotective effects","volume":"227","author":"AlNajjar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib28","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3233\/JAD-240078","article-title":"Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer\u2019s Disease and Down Syndrome","volume":"101","author":"Meijer","year":"2024","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.chembiol.2026.05.005_bib29","doi-asserted-by":"crossref","first-page":"15648","DOI":"10.1021\/acs.jmedchem.3c01888","article-title":"Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer\u2019s Disease Drug Candidate","volume":"66","author":"Lindberg","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114062","article-title":"DYRK1A inhibitors for disease therapy: Current status and perspectives","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib31","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acsmedchemlett.0c00279","article-title":"Mining Public Domain Data to Develop Selective DYRK1A Inhibitors","volume":"11","author":"Henderson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2026.05.005_bib32","first-page":"1315","article-title":"DYRK1A kinase inhibitors with emphasis on cancer","volume":"12","author":"Ionescu","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/02698811241273772","article-title":"A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers","volume":"38","author":"Ables","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71118-3","article-title":"Mito-oncology agent: fermented extract suppresses the Warburg effect, restores oxidative mitochondrial activity, and inhibits in vivo tumor growth","volume":"10","author":"Bencze","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chembiol.2026.05.005_bib35","doi-asserted-by":"crossref","first-page":"7920","DOI":"10.1021\/acs.jmedchem.5c03226","article-title":"Identification and Validation of an Inhibitor of the Protein Kinases PIM and DYRK","volume":"69","author":"Bencze","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15430\/JCP.2018.23.3.109","article-title":"PIM Kinase as an Executional Target in Cancer","volume":"23","author":"Zhang","year":"2018","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.chembiol.2026.05.005_bib37","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3390\/cancers12082106","article-title":"The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities","volume":"12","author":"Boni","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.chembiol.2026.05.005_bib38","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nprot.2006.149","article-title":"Assay of protein kinases using radiolabeled ATP: a protocol","volume":"1","author":"Hastie","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.chembiol.2026.05.005_bib39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1752-0509-5-156","article-title":"Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity","volume":"5","author":"Wynn","year":"2011","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jb\/mvr053","article-title":"Encountering unpredicted off-target effects of pharmacological inhibitors","volume":"150","author":"Miyazawa","year":"2011","journal-title":"J. Biochem. (Tokyo)"},{"key":"10.1016\/j.chembiol.2026.05.005_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2026.05.005_bib42","doi-asserted-by":"crossref","first-page":"18101","DOI":"10.1073\/pnas.0608849103","article-title":"The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity","volume":"103","author":"Emrick","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.chembiol.2026.05.005_bib43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.chembiol.2013.06.001","article-title":"Ins and outs of kinase DFG motifs","volume":"20","author":"Treiber","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib44","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1017\/S0031182014000857","article-title":"The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites","volume":"141","author":"Keyloun","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.chembiol.2026.05.005_bib45","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cGatekeeper Door\u201d: Exploiting the Active Kinase Conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib46","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1021\/cr000250y","article-title":"Chemical Inhibitors of Protein Kinases","volume":"101","author":"Bridges","year":"2001","journal-title":"Chem. Rev."},{"key":"10.1016\/j.chembiol.2026.05.005_bib47","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.bmc.2005.02.021","article-title":"Targeting the gatekeeper residue in phosphoinositide 3-kinases","volume":"13","author":"Alaimo","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0955-0674(02)00317-4","article-title":"The emerging power of chemical genetics","volume":"14","author":"Specht","year":"2002","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.stem.2010.06.021","article-title":"Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling","volume":"7","author":"Ferron","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.chembiol.2026.05.005_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2005.05.009","article-title":"BMP signaling and stem cell regulation","volume":"284","author":"Zhang","year":"2005","journal-title":"Dev. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib51","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/MCB.00394-08","article-title":"Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A","volume":"28","author":"Aranda","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib52","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1541-7786.MCR-14-0183-T","article-title":"Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma","volume":"13","author":"Walsh","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.chembiol.2026.05.005_bib53","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/neuonc\/noy028","article-title":"Sprouty2 enhances the tumorigenic potential of glioblastoma cells","volume":"20","author":"Park","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib54","first-page":"449","article-title":"DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles","volume":"25","author":"Aranda","year":"2011","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib55","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.3390\/ijms22169098","article-title":"GSK-3\u03b2, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways","volume":"22","author":"Demuro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chembiol.2026.05.005_bib56","first-page":"2084","article-title":"The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle Georget","volume":"13","author":"Soppa","year":"2014","journal-title":"Tex"},{"key":"10.1016\/j.chembiol.2026.05.005_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1742-4658.2010.07954.x","article-title":"MNB\/DYRK1A as a multiple regulator of neuronal development","volume":"278","author":"Tejedor","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.chembiol.2026.05.005_bib58","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20150002","article-title":"DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3","volume":"212","author":"Thompson","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.chembiol.2026.05.005_bib59","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00018-020-03626-4","article-title":"DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis","volume":"78","author":"Laham","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.chembiol.2026.05.005_bib60","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.celrep.2018.04.008","article-title":"DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells","volume":"23","author":"Rozen","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2026.05.005_bib61","doi-asserted-by":"crossref","first-page":"13223","DOI":"10.1074\/jbc.M110.102574","article-title":"DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1","volume":"285","author":"Guo","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib62","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41698-024-00614-w","article-title":"Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1\/S targeting chemotherapy drugs","volume":"8","author":"Laham","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12929-022-00817-y","article-title":"DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD","volume":"29","author":"Li","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.chembiol.2026.05.005_bib64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/ijms22020587","article-title":"Updated Insights on EGFR Signaling Pathways in Glioma","volume":"22","author":"Oprita","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.chembiol.2026.05.005_bib65","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/B978-0-12-802997-8.00023-2","article-title":"Glioblastoma","volume":"134","author":"Wirsching","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib66","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3892\/ol.2017.6221","article-title":"Epidermal growth factor receptor in glioblastoma","volume":"14","author":"Xu","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.chembiol.2026.05.005_bib67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/pr.117.014944","article-title":"Current Challenges and Opportunities in Treating Glioblastoma","volume":"70","author":"Shergalis","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.chembiol.2026.05.005_bib68","doi-asserted-by":"crossref","first-page":"10060","DOI":"10.1158\/0008-5472.CAN-10-2465","article-title":"Coexpression Network Analysis Identifies Transcriptional Modules Related to Proastrocytic Differentiation and Sprouty Signaling in Glioma","volume":"70","author":"Ivliev","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.05.005_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib70","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1021\/acs.jmedchem.1c00023","article-title":"Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors","volume":"64","author":"Weber","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib71","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bioinformatics\/btp650","article-title":"Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis","volume":"26","author":"Huang","year":"2010","journal-title":"Bioinforma. Oxf. Engl."},{"key":"10.1016\/j.chembiol.2026.05.005_bib72","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.7909169","article-title":"Structural Clues to Prion Replication","volume":"264","author":"Cohen","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.05.005_bib73","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1021\/acs.jmedchem.0c00898","article-title":"DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity","volume":"63","author":"Schr\u00f6der","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0163-7258(98)00044-8","article-title":"Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors","volume":"82","author":"Traxler","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.chembiol.2026.05.005_bib75","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1074-5521(99)80118-5","article-title":"Structural basis for selective inhibition of Src family kinases by PP1","volume":"6","author":"Liu","year":"1999","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib76","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/cb500696t","article-title":"DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors","volume":"10","author":"Ung","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib77","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.chembiol.2026.05.005_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.05.005_bib79","doi-asserted-by":"crossref","first-page":"8897","DOI":"10.1093\/nar\/gkae574","article-title":"Nuclear F-actin assembly on damaged chromatin is regulated by DYRK1A and Spir1 phosphorylation","volume":"52","author":"Li","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.chembiol.2026.05.005_bib80","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.molcel.2018.02.011","article-title":"LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia","volume":"69","author":"Tarumoto","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2026.05.005_bib81","doi-asserted-by":"crossref","first-page":"28557","DOI":"10.1074\/jbc.272.45.28557","article-title":"Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein","volume":"272","author":"Kamitani","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2026.05.005_bib82","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2026.05.005_bib83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data processing and analysis with the autoPROC toolbox","volume":"67","author":"Vonrhein","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.chembiol.2026.05.005_bib84","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.chembiol.2026.05.005_bib85","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX : a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.chembiol.2026.05.005_bib86","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.chembiol.2026.05.005_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity : all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945626001571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945626001571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:39:06Z","timestamp":1783010346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945626001571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2451945626001571"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2026.05.005","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}